Anirudh Joshi, Co-Founder and CEO of the Valar Labs, shared on X:
”Precision oncology is expanding in Muscle Invasive Bladder Cancer! Happy to share our collaborators’ and teams’ new peer reviewed work to develop a new AI biomarker to predict aggressiveness of MIBC tumors using upfront HandE pathology alone.
The model identified patients at 2x elevated risk of events post radical cystectomy.
This study is the first step towards the validation of a suite of algorithms in this disease to personalize therapy amongst all the new options available to patients.
We are building algorithms to personalize care across the spectrum of bladder cancer for every stage and every therapy.”
Title: Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer
Authors: Yair Lotan, Vitaly Margulis, Solomon Woldu, Derek Allison, Joon Kyung Kim, Laura Bukavina, Sam S. Chang, Vrishab Krishna, Gaurav Kaul, Akshay Neema, Haochen Zhang, Trevor J. Royce, Viswesh Krishna, Anirudh Joshi, Ashish M. Kamat, Roger Li, Patrick J. Hensley
Other articles about AI in oncology on OncoDaily.